Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

7.26
+0.34004.91%
Post-market: 7.390.1343+1.85%19:49 EDT
Volume:1.23M
Turnover:8.83M
Market Cap:140.42M
PE:-1.19
High:7.50
Open:6.86
Low:6.82
Close:6.92
52wk High:20.56
52wk Low:6.33
Shares:19.34M
Float Shares:17.42M
Volume Ratio:0.38
T/O Rate:7.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.37
PE(LYR):-1.23

Loading ...

Corbus enrolls last patient in Phase 1b CANYON-1 obesity trial of CRB-913

Reuters
·
Apr 14

Corbus Pharmaceuticals Holdings Inc - Canyon-1 Study on Track for Completion in Summer 2026

THOMSON REUTERS
·
Apr 14

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 14

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 10

Analysts Offer Insights on Healthcare Companies: Treace Medical Concepts (TMCI), Corbus Pharmaceuticals (CRBP) and Avita Medical (RCEL)

TIPRANKS
·
Apr 09

Corbus Pharmaceuticals Holdings Inc. Stock Rises Wednesday, Still Underperforms Market

Dow Jones
·
Apr 09

Corbus Pharmaceuticals (CRBP) Gets a Buy from Wedbush

TIPRANKS
·
Apr 08

Corbus Pharmaceuticals Holdings Inc. Stock Slips 4.2%, Underperforms Market

Dow Jones
·
Apr 08

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Corbus Pharmaceuticals (CRBP) and Artivion (AORT)

TIPRANKS
·
Apr 07

Corbus reports FDA alignment for CRB-701, CMO Dominic Smethurst departure

TIPRANKS
·
Apr 07

Corbus CMO Dominic Smethurst to step down June 30, 2026

Reuters
·
Apr 07

BRIEF-Corbus Pharmaceuticals Announces Broad Alignment With FDA On Registration Path For Crb-701 In Second-Line Hnscc And Cervical Cancer

Reuters
·
Apr 07

Corbus Pharmaceuticals Holdings Inc - to Continue FDA Interactions to Finalize Registration Study Protocols

THOMSON REUTERS
·
Apr 07

Corbus Pharmaceuticals price target raised to $40 from $39 at Mizuho

TIPRANKS
·
Apr 06

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 03

Corbus Pharmaceuticals announces annual stockholders meeting notice

Reuters
·
Apr 03

Mizuho Securities Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Apr 02

Mizuho Lifts Price Target on Corbus Pharmaceuticals Holdings to $40 From $39, Keeps Outperform Rating

MT Newswires Live
·
Apr 02

Corbus Pharmaceuticals Holdings Inc. Stock Rises 6.3%, Outperforms Peers

Dow Jones
·
Apr 02

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Mar 31